Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00579436 · ClinicalTrials.gov registry record · NA
Effects of Fish Oils on Inflammation and Insulin Resistance
A NA study of Insulin Resistance and Metabolic Syndrome, sponsored by Philip Kern.
- Completed
- Registry status
- NA
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT00579436: Completed NA study of Insulin Resistance and Metabolic Syndrome, sponsored by Philip Kern.
NCT00579436 is a NA study of Insulin Resistance and Metabolic Syndrome that has completed, run by Philip Kern. The registered enrollment target is 33 participants, below the 245-participant average among 120 other Insulin Resistance trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00579436, a NA study of Insulin Resistance and Metabolic Syndrome, has completed, sponsored by Philip Kern.
- COMPLETED
- Registry status
- NA
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether improvement in fat and muscle metabolism after the treatment with Omacor (fish oils) provides insight into the link between obesity, fat and muscle function leading to metabolic syndrome, which is a risk factor for heart disease and diabetes.
Primary Outcome
Prior to starting the fish oil regiment, participants will undergo an incisional abdominal biopsy to remove approximately 4g of adipose tissue to determine adipocyte size
Conditions Studied
Interventions
- DRUG placebo
- DRUG omega-3 fatty acid
Study Locations (1)
Kentucky
- University of Kentucky Medical Cener - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2007-01 |
| Est. Completion | 2015-01-15 |
| Phase | NA |
What the finished NCT00579436 record still lists
NCT00579436 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 245-participant average among 120 other Insulin Resistance trials with a reported enrollment target (87% lower).
The record links to 2 conditions, with Insulin Resistance appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00579436 reports a single indexed study location in Kentucky.
Frequently Asked Questions
What is clinical trial NCT00579436 about?
NCT00579436 is a clinical study titled "Effects of Fish Oils on Inflammation and Insulin Resistance". The purpose of this study is to determine whether improvement in fat and muscle metabolism after the treatment with Omacor (fish oils) provides insight into the link between obesity, fat and muscle function leading to metabolic syndrome, which is a risk factor for heart disease and diabetes.
What is the current status of trial NCT00579436?
This trial is currently completed. It is a NA study. The enrollment target is 33 participants. The study started on 2007-01. Estimated completion is 2015-01-15.
What conditions does trial NCT00579436 study?
This clinical trial studies the following conditions: Insulin Resistance, Metabolic Syndrome.
What interventions are being tested in trial NCT00579436?
The interventions under investigation include: placebo (DRUG), omega-3 fatty acid (DRUG).
Who is sponsoring clinical trial NCT00579436?
This trial is sponsored by Philip Kern, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00579436 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Insulin Resistance
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00579436's enrollment target sits among peer trials
33 83rd of 120 higher than 38 of 120 other Insulin Resistance trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Insulin Resistance trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Metabolic Adaptations to Weight Loss With and Without Exercise
RECRUITING · NA
-
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
RECRUITING · NA
-
Effect of Weight Loss on Intermuscular Adipose Tissue (IMAT) Signaling
RECRUITING · NA
-
Small Extracellular Vesicles and Insulin Action
RECRUITING · NA
-
Exercise Effects on Adipose Tissue Structure and Function
RECRUITING · NA
-
New Mechanisms of Obesity
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia